Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Herman

Showing results (1091-1100 of 1,237) with videos related to

Pageof 124
Sort By:
Annals of Surgery|June 10, 2010
Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysisMechteld C De Jong, Michael B Farnell, Guido Sclabas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2014
A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosisKim A Reiss, Joseph M Herman, Marianna Zahurak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2015
Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination TherapyMartin Skarzynski, Carsten U Niemann, Yuh Shan Lee, et al.
International Journal of Radiation Oncology, Biology, Physics|August 29, 2020
Executive Summary of the American Radium Society Appropriate Use Criteria for Operable Esophageal and Gastroesophageal Junction Adenocarcinoma: Systematic Review and GuidelinesChristopher J Anker, Jadranka Dragovic, Joseph M Herman, et al.
Leukemia|July 20, 2016
Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemiaL M Saleh, W Wang, S E M Herman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 19, 2014
Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancerJulius Chapiro, Surojit Sur, Lynn Jeanette Savic, et al.
Practical Radiation Oncology|April 16, 2013
Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiationSonali Rudra, Amol K Narang, Timothy M Pawlik, et al.
Annals of Surgical Oncology|February 26, 2013
Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial designMatthew H G Katz, Robert Marsh, Joseph M Herman, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|September 14, 2011
Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, single institution experiencePeter J Kneuertz, Steven C Cunningham, John L Cameron, et al.
Blood|August 14, 2013
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patientsBetty Y Chang, Michelle Francesco, Martin F M De Rooij, et al.
Pageof 124

Showing results (1091-1100 of 1,237) with videos related to

Sort By:
Pageof 124
Annals of Surgery|June 10, 2010
Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysisMechteld C De Jong, Michael B Farnell, Guido Sclabas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 31, 2014
A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosisKim A Reiss, Joseph M Herman, Marianna Zahurak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 19, 2015
Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination TherapyMartin Skarzynski, Carsten U Niemann, Yuh Shan Lee, et al.
International Journal of Radiation Oncology, Biology, Physics|August 29, 2020
Executive Summary of the American Radium Society Appropriate Use Criteria for Operable Esophageal and Gastroesophageal Junction Adenocarcinoma: Systematic Review and GuidelinesChristopher J Anker, Jadranka Dragovic, Joseph M Herman, et al.
Leukemia|July 20, 2016
Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemiaL M Saleh, W Wang, S E M Herman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 19, 2014
Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancerJulius Chapiro, Surojit Sur, Lynn Jeanette Savic, et al.
Practical Radiation Oncology|April 16, 2013
Evaluation of predictive variables in locally advanced pancreatic adenocarcinoma patients receiving definitive chemoradiationSonali Rudra, Amol K Narang, Timothy M Pawlik, et al.
Annals of Surgical Oncology|February 26, 2013
Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial designMatthew H G Katz, Robert Marsh, Joseph M Herman, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|September 14, 2011
Palliative surgical management of patients with unresectable pancreatic adenocarcinoma: trends and lessons learned from a large, single institution experiencePeter J Kneuertz, Steven C Cunningham, John L Cameron, et al.
Blood|August 14, 2013
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patientsBetty Y Chang, Michelle Francesco, Martin F M De Rooij, et al.
Pageof 124